GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosesimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177) , a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evalsuating BAT8009, an antibody drug conjugate (ADC) that targets B7-H3 (CD276). The clinical trial is a multicent...
Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177) , a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in a Phase 1 clinical study evalsuatingBAT8006, an antibody drug conjugate (ADC) that targets folic acid receptor α(FRα). The clinical trial is...
Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177) , a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in a Phase 1 clinical study to evalsuatethe safety, t olerability,pharmacokinetics, and preliminary efficacy of BAT7104, a bispecific antibodytha...
